Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Jacek Baj
 -- 2412 2022-06-20 08:46:43 |
2 format correct
Catherine Yang
 Meta information modification 2412 2022-06-20 08:57:42 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Baj, J.;  Forma, A.;  Teresińska, B.;  Tyczyńska, M.;  Zembala, J.;  Januszewski, J.;  Flieger, J.;  Buszewicz, G.;  Teresiński, G. SARS-CoV-2 Affect Eyes. Encyclopedia. Available online: https://encyclopedia.pub/entry/24204 (accessed on 03 July 2024).
Baj J,  Forma A,  Teresińska B,  Tyczyńska M,  Zembala J,  Januszewski J, et al. SARS-CoV-2 Affect Eyes. Encyclopedia. Available at: https://encyclopedia.pub/entry/24204. Accessed July 03, 2024.
Baj, Jacek, Alicja Forma, Barbara Teresińska, Magdalena Tyczyńska, Julita Zembala, Jacek Januszewski, Jolanta Flieger, Grzegorz Buszewicz, Grzegorz Teresiński. "SARS-CoV-2 Affect Eyes" Encyclopedia, https://encyclopedia.pub/entry/24204 (accessed July 03, 2024).
Baj, J.,  Forma, A.,  Teresińska, B.,  Tyczyńska, M.,  Zembala, J.,  Januszewski, J.,  Flieger, J.,  Buszewicz, G., & Teresiński, G. (2022, June 20). SARS-CoV-2 Affect Eyes. In Encyclopedia. https://encyclopedia.pub/entry/24204
Baj, Jacek, et al. "SARS-CoV-2 Affect Eyes." Encyclopedia. Web. 20 June, 2022.
SARS-CoV-2 Affect Eyes
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11123379

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has become a worldwide threat resulting in a pandemic in 2020. SARS-CoV-2 infection manifests itself as coronavirus disease 2019 (COVID-19) that is evidenced in a vast number of either specific or nonspecific symptoms. Except for typical (but nonspecific) symptoms such as fever, dry cough, or muscle weakness, the infected patients might also present atypical symptoms including neurological, dermatological, or ophthalmic manifestations.

ophthalmic manifestations SARS-CoV-2 atypical symptom

1. Introduction

Severe acute respiratory syndrome, coronavirus 2 (SARS-CoV-2), which can cause coronavirus disease 2019 (COVID-19), was first observed in the city of Wuhan, China in late 2019 [1]. The infection induced by the virus can spread rapidly and may lead to serious systemic complications, especially those associated with the respiratory system [1][2]. The disease was announced as a pandemic in March 2020 with an infection rate of about 291,000,000 between December 2019 and January 2022, causing nearly 5,500,000 deaths [2][3]. SARS-CoV-2 is a single, positive-stranded RNA beta coronavirus that has transmitted and spread all over the world since January 2020 [2][4]. The transmission (mainly by aerosol and droplets) is related to the angiotensin-converting enzyme 2 (ACE2) receptor located in the membrane of the lungs, heart, kidneys, or ocular cells to which the coronavirus attaches [4]. COVID-19 manifests itself as flu-like condition but can expose many other symptoms, frequently of an unusual nature [4].
SARS-CoV-2 impacts different systems of the human body. Some patients exhibit nonspecific symptoms, such as headache, nausea, vomiting, dizziness, and confusion, while some present with more specific ones such as: seizures and cerebrovascular disorders [5][6]. COVID-19 can also lead to some serious cardiovascular complications [7]. Furthermore, the frequency of acute kidney injury (AKI) in patients with COVID-19 is quite common; besides that, SARS-CoV-2 presented a tropism in female and male reproductive organs [8][9]. What is more, some cutaneous manifestations of COVID-19, which include maculopapular, chilblain-like, urticarial, vesicular, livedoid, and petechial lesions, are observed (Table 1).
Table 1. Comparison of typical and atypical COVID-19 infection symptoms.
Typical Manifestations Atypical Manifestations
Fever Kawasaki-like disease
Cough Cerebrovascular disorders
Fatigue Cutaneous manifestations
Headache AKI
Loss of smell and taste Conjunctival congestions
Dyspnea Seizure
Pediatric patients with SARS-CoV-2 usually have a higher rate of mild infection than adults and present fewer complications. Over one-third of pediatric patients present normal chest computed tomography (CT) scans. The most common radiological findings regardless of patients’ age include ground glass opacities and the presence of consolidations or pneumonic infiltrates.
Most infected patients prove to have a higher rate of the following biomarkers—C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, renal biomarkers, lymphocytes, and platelet Mount [10]. Concerning the accuracy of SARS-CoV-2 diagnostic tests, RT-PCR remains the gold standard for COVID-19 diagnosis. The combination of IgM and IgG antibodies also demonstrated promising results as for sensitivity and specificity [11].

2. Pathophysiology and Transmission of SARS-CoV-2 Infection

SARS-CoV-2 is a 45726 single-stranded positive-sense RNA virus classified as betacoronaviridae. It can spread in many ways in the form of aerosols, droplets, or conjunctival transmission [1][12]. Following the entry, mainly due to the ACE-2 receptor, the virion binds to the host cells and enters the cells through endocytosis or membrane fusion [11]. ACE-2 receptors are found in almost every organ, such as the lungs, heart, kidneys, or gastrointestinal system. This could partially explain some atypical symptoms and dangerous complications of SARS-CoV-2 infection [1][13]. As presented earlier, following entry, the virus releases its RNA in the epithelial cells (ECs) [1]. In infected Ecs, inflammation; abnormal cytokine release (VEGF, MCP-1, and IL-8); and tissue damage are consecutively observed [1]. All these disorders might eventually lead to multiorgan failure or acute respiratory distress syndrome (ARDS) [1].
Transmission is possible owing to droplets and other body fluids, air, and fomite. There is also a possibility of conjunctival transmission; aerosols < 5 μm in diameter can cause airborne transmission [14]. Infected tears or respiratory droplets may come into contact with the conjunctiva and lead to SARS-CoV-2 infection [15].

3. SARS-CoV-2 Infection Effect in Eyes

3.1. Episcleritis

A study from Turkey found a 2.2% prevalence of episcleritis in COVID-19 patients [16]. It was also shown that episcleritis was associated with higher D-dimer levels. In another case, episcleritis developed after the main COVID-19 respiratory symptoms were resolved, and the patient reported to the ophthalmologic clinic with red eyes, foreign body sensations, epiphora, and photophobia. Nodular episcleritis was diagnosed [17]. A case of episcleritis in a 29-year-old male who was diagnosed 3 days before the onset of full-blown COVID-19 has also been reported [18]. About one-third of cases can be associated with viral infections, such as Ebola, hepatitis B virus (HBV), hepatitis C virus (HCV), and herpes zoster virus (HZV), and also, the immune-vascular factors and thrombotic complications of COVID-19 have evoked suspicion in the role of COVID-19 in developing episcleritis [19].

3.2. Kawasaki Disease

Children suffer from COVID-19 more mildly, mainly because of more effective immune responses [20]. The prevalence of conjunctivitis in infected children is estimated to be low (1–5%) [21]. However, an increase in morbidity of Kawasaki disease has been noticed, presenting as vasculitis of small and medium vessels that also results in fever, lymphadenopathy, cutaneous and palmar–plantar erythema, conjunctivitis, limb edema, and less frequently, coronary aneurysms [22]. The ocular manifestations are mostly: iridocyclitis, punctate keratitis, vitreous opacities, papilledema, subconjunctival hemorrhage, and conjunctival injection [23]. The majority of patients present with better clinical outcomes in a few days, but some children (0.5–5%) might present toxic shock [22]. A case of a 6-month-old baby with generalized erythema and conjunctivitis has also been described in the literature; the child completely recovered after a treatment with intravenous immunoglobulins (IG) over 48 h [24].
Verdoni et al., conducted a comparative study of two groups—(1) 19 children with a ‘Kawasaki-like’ disease before the start of the SARS-CoV-2 outbreak in Lombardia and (2) 10 children with the disease after the start of the pandemic there [25]. The second group was observed to have had a higher mean age (7.5 years vs. 3 years); the majority had AC antibodies against the virus (8 out of 10) and suffered from a more severe form of the disease: greater cardiac involvement (6 out of 10 vs. 2 out of 19), toxic shock syndrome (5 of 10 vs. 0 of 19), and macrophage activation syndrome (5 of 10 vs. 0 of 19). Thus, SARS-CoV-2 could have been a strong stimulus in the host capable of triggering a disproportionate immune response. The predictors of this response are still unknown.

3.3. Opthalmoparesis Consistent with Abducens Nerve Palsies

Two cases of patients with a diagnosis of COVID-19 after presenting with diplopia and ophthalmoparesis were described [26]. The combination of ophthalmoparesis with bilateral abducens nerve palsies, leg paresthesia, and areflexia in the first case could suggest acute demyelinating inflammatory polyneuropathy secondary to a virus-mediated immune response. In the second case, although the radiological evidence of abducens nerve involvement was missing, the presence of painless diplopia and abduction palsy of the right eye might reflect viral leptomeningeal invasion. The event of cranial neuropathies ought to provoke the consideration of SARS-CoV-2 infection in patients with even gentle symptoms and signs of SARS-CoV-2 infection.

3.4. Oculomotor Nerve Palsy

The clinical presentation of oculomotor nerve palsy includes ptosis and the restriction of adduction, elevation, and depression movements of the eyeball. The case of a 55-year-old male with confirmed SARS-CoV-2 infection and diagnosed with third cranial nerve palsy was described. The patient was treated supportively for his infection and remained stable on room air during his hospitalization. No connective factors other than COVID-19 were identified as a cause for his cranial third nerve palsy, which resolved spontaneously during outpatient follow-up. The pathogenesis and prognosis of cranial nerve palsy in SARS-CoV-2 infection are still unclear [27]. Another reported case of acquired non-pupil-sparing oculomotor nerve palsy in a previously asymptomatic child indicated a possible link to SARS-CoV-2 infection. The patient, in contrast to oculomotor nerve palsies caused by presumed inflammation, presented no findings in the MRI. Regarding the patient’s spontaneous improvement, researchers hypothesized that the damage to the oculomotor nerve caused by SARS-CoV-2 was not permanent and that oculomotor nerve palsy could resolve spontaneously within a short time [28].

3.5. Cerebrovascular Accident (CVA) with Vision Loss

Vision loss can be the most disabling residual effect after cerebral infarction; temporary vision problems can equally be an indication of stroke, and a prompt evaluation after recognition of the visual signs can prevent future vascular injury [29]. In the COVID-19 era, vigilance for cerebrovascular complications of the aforementioned illness is needed. Scientists presented a case of bilateral occipitotemporal infarction observed as a sudden cortical loss of vision with hemorrhagic transformation after intravenous thrombolysis in a patient with diabetes infected by SARS-CoV-2 [30]. It is currently known that SARS-CoV-2 can penetrate the brain, leading to neuronal defects. Moreover, it is suggested that SARS-CoV-2 could, due to its cerebrovascular system effects, possibly provoke neuronal complications. Early data show that stroke can be one of the leading neurological complications in COVID-19 patients [31].

3.6. Acute Angle Closure Glaucoma and Horner’s Syndrome as Complications of ICU Treatment

Nerlikar et al., reported the case of a 53-year-old male with ocular discomfort and blurred vision in both eyes that was caused by prone positioning during ventilation for COVID-19 pneumonia. The patient was under sedation and was placed for 8 h in a prone position every day for 2 weeks. Additionally, he could not manifest his symptoms, so the detection and treatment were shifted over time. Moreover, it was also suggested that the medication that was given to the patient, such as Glycopyrrolate, Noradrenaline, and Salbutamol, could cause acute angle closure. Another possible reason for elevated intraocular pressure could be steroids [32].
A similar study described a patient admitted to the ICU due to COVID-19 who developed acute closure glaucoma after the use of ipratropium bromide and salbutamol, darkroom conditions, and prone positioning for 3 weeks. Despite treatment with eye drops and cataract surgery, the patient lost vision in her right eye [33]. Other studies have also indicated that some anticholinergics, sympathomimetics, and other drugs may induce AACG [34][35].
Other researchers strive to explain the main mechanisms of acute angle closure glaucoma caused by drugs. The first hypothesis assumes pupillary block and iridocorneal angle closure, and the second one blames the mass effect, which causes anterior displacement of the lens–iris diaphragm [36]. According to some studies, SARS-CoV-2 infection is not directly related to acute angle-closure glaucoma; however, it possibly contributes to AACG due to a prolonged prone position and some medications used in the treatment of COVID-19-related pneumonia.
Horner’s syndrome is characterized by ptosis, miosis, enophthalmos, and, rarely, a lack of sweating on the affected side of the face [37]. So far, the data on COVID-19-related Horner’s syndrome are still limited, but some reports have confirmed a correlation. The first report presented a 65-year-old female who tested positive for SARS-CoV-2 and was admitted to the hospital due to hypoxemia. The next day, she developed ptosis and miosis and was diagnosed with Horner’s syndrome. Despite the lack of an unequivocal mechanism and significant examination explaining the appearance of Horner’s syndrome, in this case, the influence of the SARS-CoV-2 infection could be associated with the development of ptosis and miosis 2 days after the COVID-19 diagnosis [38].
Other researchers described a 38-year-old patient with left ptosis, fever, general weakness, mild headache, slight left pupil construction, and left enophthalmos. Horner’s syndrome was diagnosed based on a neurological examination. Further, the chest CT and RT-PCR test detected SARS-CoV-2 infection. The mechanism of this syndrome, in this case, is debatable. It was suggested that it could be related to the inflammation of the upper lobe of the lungs or a reactive enlargement of the cervical lymph nodes. Another reason might be the direct impact of the virus on the nervous system [39].

3.7. Miller Fisher Syndrome

There have been several cases describing post-COVID-19 Miller Fisher syndrome, and they all presented similar symptoms and evolution [40][41][42][43][44][45][46]. Neurological symptoms were usually observed 5–20 days after the COVID-19 diagnosis [40][41][42][43][44][45][46]. The most common symptoms related to MFS included paresthesia, ophthalmoplegia, blurred vision, ataxia, areflexia, and others. It remains uncertain whether post-COVID-19 MFS is induced by viral neurotropism or the disturbed immune response. The presence of a GQ1b antibody, increased proinflammatory cytokines in the plasma, and the absence of SARS-CoV-2 in the cerebrospinal fluid suggest immune-mediated injury. However, when the testing for anti-GQ1b is negative, the pathogenesis could be explained by the neuroinvasive capacity of SARS-CoV-2 [40][47]. Generally, most cases of MFS show positive anti-GQ1b, but it is not an obligatory sign of a MFS diagnosis. Moreover, the presence of GQ1b antibodies indicates a faster recovery. According to the studies, most patients have responded well to intravenous immunoglobulin [40]. Of note, post-COVID-19 MFS was also reported in a 7-year-old child [43].

3.8. Xerophtalmia

A vitamin A deficiency might lead to various ocular symptoms, including conjunctival and corneal xerosis, Bitot’s spots, keratomalacia, nyctalopia, and retinopathy, which refer to xerophthalmia. So far, the data on xerophthalmia as a COVID-19 complication are still limited [48][49][50]. The research paper about ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China, reported that some patients with COVID-19 had chronic ocular diseases, such as xerophthalmia (24 patients, 4.5%). However, this conclusion was found additionally and was not the subject of the study. The association between COVID-19 and xerophthalmia still remains unclear [51]. Other researchers referenced this study showing that, so far, no other study has been performed on this matter, and the knowledge about xerophthalmia as a complication of SARS-CoV-2 infection is still insufficient [52][53].

3.9. Mucormycosis

SARS-CoV-2 infection might induce opportunistic fungal infections, such as pulmonary aspergillosis, pneumocystis pneumonia, oral candidiasis, or, rarely, mucormycosis [54]. Despite that, the amount of the literature reporting COVID-19-related mucormycosis is continually increasing. A major risk factor is the use of corticosteroids while managing a severe course of COVID-19. Additionally, it was reported that diabetic patients are more predisposed toward acquiring mucormycosis [55][56][57][58]. Other risk factors include neutropenia and hematologic cancers, stem cell transplant patients, and immunity-reduced patients [59]. The most common predilections were nasal, rhino-orbital, and rhino-orbital–cerebral mucormycosis [56][60][61].
A recent review by Singh et al., showed that SARS-CoV-2-infected males (78,9%) were more prone to mucormycosis than females. Furthermore, 80% of the patients had diabetes and 14.9% presented diabetic ketoacidosis. Corticosteroids were used in 76.3% of the cases. The most common was mucormycosis of the nose and sinuses, and the second was rhino-orbital. Fatalities were reported in 30% of the cases [60].

3.10. Endogenous Endophthalmitis

Endogenous endophthalmitis is usually reported in patients with numerous coexisting comorbidities, as well as those with prolonged hospitalization, intravenous mediations, or corticosteroid/immunosuppression therapy. Nayak et al. (2021), in their cohort study, presented that SARS-CoV-2 infection might be associated with an onset of endogenous endophthalmitis. The researchers observed that the prolonged administration of three drugs—namely, systemic corticosteroids, broad-spectrum antibiotics, and IL-6 inhibitors (tocilizumab)—predisposed the patients toward the onset of endogenous endophthalmitis [62]. Additionally, Bilgic et al. (2021) reported three cases of endogenous bacterial endophthalmitis in patients during their COVID-19 recovery stage [63].

References

  1. Singh, H.; Kaur, H.; Singh, K.; Sen, C.K. Cutaneous Manifestations of COVID-19: A Systematic Review. Adv. Wound Care 2021, 10, 51–80.
  2. Yesudhas, D.; Srivastava, A.; Gromiha, M.M. COVID-19 outbreak: History, mechanism, transmission, structural studies and therapeutics. Infection 2021, 49, 199–213.
  3. Haussner, W.; DeRosa, A.P.; Haussner, D.; Tran, J.; Torres-Lavoro, J.; Kamler, J.; Shah, K. COVID-19 associated myocarditis: A systematic review. Am. J. Emerg. Med. 2022, 51, 150–155.
  4. Mashayekhi, F.; Seirafianpour, F.; Pour Mohammad, A.; Goodarzi, A. Severe and life-threatening COVID-19-related mucocutaneous eruptions: A systematic review. Int. J. Clin. Pract. 2021, 75, e14720.
  5. Asadi-Pooya, A.A.; Simani, L. Central nervous system manifestations of COVID-19: A systematic review. J. Neurol. Sci. 2020, 413, 116832.
  6. Collantes, M.E.V.; Espiritu, A.I.; Sy, M.C.C.; Anlacan, V.M.M.; Jamora, R.D.G. Neurological Manifestations in COVID-19 Infection: A Systematic Review and Meta-Analysis. Can. J. Neurol. Sci. 2021, 48, 66–76.
  7. Baj, J.; Karakuła-Juchnowicz, H.; Teresiński, G.; Buszewicz, G.; Ciesielka, M.; Sitarz, R.; Forma, A.; Karakuła, K.; Flieger, W.; Portincasa, P.; et al. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. J. Clin. Med. 2020, 9, 1753.
  8. Smarz-Widelska, I.; Grywalska, E.; Morawska, I.; Forma, A.; Michalski, A.; Mertowski, S.; Hrynkiewicz, R.; Niedźwiedzka-Rystwej, P.; Korona-Glowniak, I.; Parczewski, M.; et al. Pathophysiology and Clinical Manifestations of COVID-19-Related Acute Kidney Injury—The Current State of Knowledge and Future Perspectives. Int. J. Mol. Sci. 2021, 22, 7082.
  9. Markiewicz-Gospodarek, A.; Wdowiak, P.; Czeczelewski, M.; Forma, A.; Flieger, J.; Januszewski, J.; Radzikowska-Büchner, E.; Baj, J. The Impact of SARS-CoV-2 Infection on Fertility and Female and Male Reproductive Systems. J. Clin. Med. 2021, 10, 4520.
  10. Kermali, M.; Khalsa, R.K.; Pillai, K.; Ismail, Z.; Harky, A. The role of biomarkers in diagnosis of COVID-19—A systematic review. Life Sci. 2020, 254, 117788.
  11. Böger, B.; Fachi, M.M.; Vilhena, R.O.; Cobre, A.F.; Tonin, F.S.; Pontarolo, R. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. Am. J. Infect. Control 2021, 49, 21–29.
  12. Parasher, A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad. Med. J. 2021, 97, 312–320.
  13. Trougakos, I.P.; Stamatelopoulos, K.; Terpos, E.; Tsitsilonis, O.E.; Aivalioti, E.; Paraskevis, D.; Kastritis, E.; Pavlakis, G.N.; Dimopoulos, M.A. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J. Biomed. Sci. 2021, 28, 9.
  14. Tabatabaeizadeh, S.A. Airborne transmission of COVID-19 and the role of face mask to prevent it: A systematic review and meta-analysis. Eur. J. Med. Res. 2021, 26, 1.
  15. Dockery, D.M.; Rowe, S.G.; Murphy, M.A.; Krzystolik, M.G. The Ocular Manifestations and Transmission of COVID-19: Recommendations for Prevention. J. Emerg. Med. 2020, 59, 137–140.
  16. Bostanci Ceran, B.; Ozates, S. Ocular manifestations of coronavirus disease 2019. Graefes. Arch Clin. Exp. Ophthalmol. 2020, 258, 1959–1963.
  17. Roshanshad, A.; Ashraf, M.A.; Roshanshad, R.; Kharmandar, A.; Zomorodian, S.A.; Ashraf, H. Ocular Manifestations of Patients with Coronavirus Disease 2019: A Comprehensive Review. J. Ophthalmic Vis. Res. 2021, 16, 234–247.
  18. Otaif, W.; Al Somali, A.I.; Al Habash, A. Episcleritis as a possible presenting sign of the novel coronavirus disease: A case report. Am. J. Ophthalmol. Case Rep. 2020, 20, 100917.
  19. Mangana, C.M.; Kargacin, A.B.; Barraquer, R.I. Episcleritisasanocular manifestation in a patient with COVID-19. Acta Ophthalmol. 2020, 98, e1056–e1057.
  20. Brodin, P. Why is COVID-19 so mild in children? Acta Paediatr. 2020, 109, 1082–1083.
  21. Nickbakhsh, S.; Mair, C.; Matthews, L.; Reeve, R.; Johnson, P.; Thorburn, F.; von Wissmann, B.; Reynolds, A.; McMenamin, J.; Gunson, R.N.; et al. Virus-virus interactions impact the population dynamics of influenza and the common cold. Proc. Natl. Acad. Sci. USA 2019, 116, 27142–27150.
  22. Zimmermann, P.; Curtis, N. Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr. Infect. Dis. J. 2020, 39, 355–368.
  23. Bertoli, F.; Veritti, D.; Danese, C.; Samassa, F.; Sarao, V.; Rassu, N.; Gambato, T.; Lanzetta, P. Ocular findings in COVID-19 patients: A review of direct manifestations and indirect effects on the eye. J. Ophthalmol. 2020, 2020, 4827304.
  24. Wu, P.; Liang, L.; Chen, C.B.; Nie, S.Q. A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis. Graefes. Arch Clin. Exp. Ophthalmol. 2020, 258, 1565–1566.
  25. Verdoni, L.; Mazza, A.; Gervasoni, A.; Martelli, L.; Ruggeri, M.; Ciuffreda, M.; Bonanomi, E.; D’Antiga, L. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet 2020, 395, 1771–1778.
  26. Dinkin, M.; Gao, V.; Kahan, J.; Bobker, S.; Simonetto, M.; Wechsler, P.; Harpe, J.; Greer, C.; Mints, G.; Salama, G.; et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology 2020, 95, 221–223.
  27. Douedi, S.; Naser, H.; Mazahir, U.; Hamad, A.I.; Sedarous, M. Third Cranial Nerve Palsy Due to COVID-19 Infection. Cureus 2021, 13, e14280.
  28. de Oliveira, M.R.; Lucena, A.R.V.P.; Higino, T.M.M.; Ventura, C.V. Oculomotor nerve palsy in an asymptomatic child with COVID-19. J. Am. Assoc. Pediatr. Ophthalmol. Strabismus 2021, 25, 169–170.
  29. Pula, J.H.; Yuen, C.A. Eyes and stroke: The visual aspects of cerebrovascular disease. Stroke Vasc. Neurol. 2017, 2, 210–220.
  30. Bonardel, C.; Bonnerot, M.; Ludwig, M.; Vadot, W.; Beaune, G.; Chanzy, B.; Cornut, L.; Baysson, H.; Farines, M.; Combes, I.; et al. Bilateral posterior cerebral artery territory infarction in a SARS-CoV-2 infected patient: Discussion about an unusual case. J. Stroke Cerebrovasc. Dis. 2020, 29, 105095.
  31. Andrabi, M.S.; Andrabi, S.A. Neuronal and Cerebrovascular Complications in Coronavirus Disease 2019. Front. Pharmacol. 2020, 11, 570031.
  32. Nerlikar, R.R.; Palsule, A.C.; Vadke, S. Bilateral Acute Angle Closure Glaucoma After Prone Position Ventilation for COVID-19 Pneumonia. J. Glaucoma 2021, 30, e364–e366.
  33. Lozano, R.E.R.; Galvan-Lopez, C.A.; Garza-Garza, L.A.; Rodriguez-Valdes, P.J. Acute angle closure glaucoma in a patient admitted at the intensive care unit for the management of COVID-19. Pan-Am. J. Ophthalmol. 2021, 3, 16.
  34. Petsas, A.; Chapman, G.; Stewart, R. Acute angle closure glaucoma—A potential blind spot in critical care. J. Intensive Care Soc. 2017, 18, 244–246.
  35. Singer Michael, S.; Sarwat, S. Bilateral acute angle-closure glaucoma as a complication of facedown spine surgery. Spine J. 2010, 10, e7–e9.
  36. Yang, M.C.; Lin, K.Y. Drug-induced Acute Angle-closure Glaucoma: A Review. J. Curr. Glaucoma Pract. 2019, 13, 104–109.
  37. Martin Timothy, J. Horner syndrome: A clinical review. ACS Chem. Neurosci. 2018, 9, 177–186.
  38. Naor, M.S.; Mathew, P.G.; Sharon, R. Transient Horner syndrome associated with COVID-19: A case report. eNeurologicalSci 2021, 25, 100349.
  39. Popiołek, A.; Chyrek-Tomaszewska, A.; Kłopocki, J.; Dura, M.; Pulkowski, G. Horner’s syndrome in the course of COVID-19: A case report. Med. Res. J. 2021, 6, 274–275.
  40. Gutiérrez-Ortiz, C.; Méndez-Guerrero, A.; Rodrigo-Rey, S.; Pedro-Murillo, E.S.; Bermejo-Guerrero, L.; Gordo-Mañas, R.; de Aragón-Gómez, F.; Benito-León, J. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology 2020, 95, e601–e605.
  41. Ray, A. Miller Fisher syndrome and COVID-19: Is there a link? BMJ Case Rep. 2020, 13, e236419.
  42. Senel, M.; Abu-Rumeileh, S.; Michel, D.; Garibashvili, T.; Althaus, K.; Kassubek, J.; Otto, M. Miller-Fisher syndrome after COVID-19: Neurochemical markers as an early sign of nervous system involvement. Eur. J. Neurol. 2020, 27, 2378–2380.
  43. Biswas, S.; Ghosh, R.; Mandal, A.; Pandit, A.; Roy, D.; Sengupta, S.; De, K.; waika, B.C.; Benito-Leon, J. COVID-19 Induced Miller Fisher Syndrome Presenting With Autonomic Dysfunction: A Unique Case Report and Review of Literature. Neurohospitalist 2022, 12, 111–116.
  44. Reyes-Bueno, J.A.; Garcia-Trujillo, L.; Urbaneja, P.; Ciano-Petersen, N.L.; Postigo-Pozo, M.J.; Martinez-Tomas, C.; Serrano-Castro, P.J. Miller-Fisher syndrome after SARS-CoV-2 infection. Eur. J. Neurol. 2020, 27, 1759–1761.
  45. Manganotti, P.; Pesavento, V.; Stella, A.B.; Bonzi, L.; Campagnolo, E.; Bellavita, G.; Fabris, B.; Luzzati, R. Miller Fisher syndrome diagnosis and treatment in a patient with SARS-CoV-2. J. Neurovirol. 2020, 26, 605–606.
  46. Kajani, S.; Kajani, R.; Huang, C.W.; Tran, T.; Liu, A.K. Miller Fisher Syndrome in the COVID-19 Era—A Novel Target Antigen Calls for Novel Treatment. Cureus 2021, 13, e12424.
  47. Lowery, M.M.; Taimur Malik, M.; Seemiller, J.; Tsai, C.S. Atypical Variant of Guillain Barre Syndrome in a Patient with COVID-19. J. Crit. Care Med. 2020, 6, 231–236.
  48. McLaren, D.S.; Kraemer, K. Xerophthalmia. World Rev. Nutr. Diet. 2012, 103, 65–75.
  49. Feroze, K.B.; Kaufman, E.J. Xerophthalmia. In StatPearls ; StatPearls Publishing: Treasure Island, FL, USA, 2022. Available online: https://www.ncbi.nlm.nih.gov/books/NBK431094 (accessed on 24 March 2022).
  50. Pitak-Arnnop, P.; Meningaud, J.P.; Sirintawat, T.; Subbalekha, K.; Auychai, P.; Iamaroon, A.; O-Charoenrat, P.; Suntorntham, S.; Messer-Peti, R.; Neff, A. A German AWMF’s S2e/realist synthesis and meta-narrative snapshot of craniomaxillofacial manifestations in COVID-19 patients: Rapid living update on 1 January 2021. J. Stomatol. Oral Maxillofac. Surg. 2021, 123, 64–73.
  51. Chen, L.; Deng, C.; Chen, X.; Zhang, X.; Chen, B.; Yu, H.; Qin, Y.; Xiao, K.; Zhang, H.; Sun, X. Ocular manifestations and clinical characteristics of 534 cases of COVID-19 in China: A cross-sectional study. medRxiv 2020, 98, e951–e959.
  52. Sánchez-Tena, M.Á.; Martinez-Perez, C.; Villa-Collar, C.; Alvarez-Peregrina, C. Impact of COVID-19 at the ocular level: A citation network study. J. Clin. Med. 2021, 10, 1340.
  53. Gulias-Cañizo, R.; Ruíz-Leyja, E.D.; Sánchez-Huerta, V.; Ochoa-de la Paz, L. SARS-CoV-2 and the Eye: A Relationship for a Possible Prognostic Tool in COVID-19 Patients. Clin. Ophthalmol. 2021, 15, 707–712.
  54. Salehi, M.; Ahmadikia, K.; Badali, H.; Khodavaisy, S. Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran. Mycopathologia 2020, 185, 607–611.
  55. Lionakis, M.S.; Kontoyiannis, D.P. Glucocorticoids and invasive fungal infections. Lancet 2003, 362, 1828–1838.
  56. Garg, D.; Muthu, V.; Sehgal, I.S.; Ramachandran, R.; Kaur, H.; Bhalla, A.; Puri, G.D.; Chakrabarti, A.; Agarwal, A. Coronavirus Disease (COVID-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia 2021, 186, 289–298.
  57. Al-Tawfiq, J.A.; Alhumaid, S.; Alshukairi, A.N.; Temsah, M.H.; Barry, M.; Al Mutair, A.; Rabaan, A.A.; Al-Omari, A.; Tirupathi, R.; AlQahtani, M.; et al. COVID-19 and mucormycosis superinfection: The perfect storm. Infection 2021, 49, 833–853.
  58. John, T.M.; Jacob, C.N.; Kontoyiannis, D.P. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J. Fungi 2021, 7, 298.
  59. Werthman-Ehrenreich, A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am. J. Emerg. Med. 2021, 42, 264.e5–264.e8.
  60. Singh, A.K.; Singh, R.; Joshi, S.R.; Misra, A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab. Syndr. Clin. Res. Rev. 2021, 15, 102146.
  61. Selarka, L.; Sharma, S.; Saini, D.; Sharma, S.; Batra, A.; Waghmare, V.T.; Dileep, P.; Patel, S.; hah, M.; Parikh, T.; et al. Mucormycosis and COVID-19: An epidemic within a pandemic in India. Mycoses 2021, 64, 1253–1260.
  62. Nayak, S.; Das, T.; Parameswarappa, D.; Sharma, S.; Jakati, S.; Jalali, S.; Narayanan, R.; Basu, S.; Tyagi, M.; Dave, V.P. Sight-threatening intraocular infection in patients with COVID-19 in India. Indian J. Ophthalmol. 2021, 69, 3664–3676.
  63. Bilgic, A.; Sudhalkar, A.; Gonzalez-Cortes, J.H.; March de Ribot, F.; Yogi, R.; Kodjikian, L.; Mathis, T. Endogenous endophthalmitis in the setting of COVID-19 infection: A case series. Retina 2021, 41, 1709–1714.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Ophthalmology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Jacek Baj
,
Alicja Forma
,
Barbara Teresińska
,
Magdalena Tyczyńska
,
Julita Zembala
,
Jacek Januszewski
,
Jolanta Flieger
,
Grzegorz Buszewicz
,
Grzegorz Teresiński
View Times: 679
Entry Collection: COVID-19
Revisions: 2 times (View History)
Update Date: 20 Jun 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback